The Role of H3.3 histone variant in the pathogenesis of oral Kaposi's Sarcoma
H3.3组蛋白变异在口腔卡波西肉瘤发病机制中的作用
基本信息
- 批准号:10418661
- 负责人:
- 金额:$ 35.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-04 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS related cancerATRX geneAcquired Immunodeficiency SyndromeAddressAffectB-LymphocytesBindingBiologyBiopsyCRISPR/Cas technologyCell LineCellsChromatinChromatin StructureClinicalCollaborationsDataDentistryDepositionEndothelial CellsEpigenetic ProcessEpisomeEpithelialEpithelial CellsEquilibriumEtiologyFormalinFreezingGene ExpressionGenesGenetic TranscriptionGenomeGingivaGoalsGrowthHIVHead and neck structureHerpesviridaeHistone H3HistonesHorizontal Disease TransmissionHourHumanHuman Herpesvirus 8IncidenceIndividualInfectionKaposi SarcomaKnock-inKnock-outLymphoidLymphoid CellLymphoma cellLymphoproliferative DisordersLyticLytic PhaseMaintenanceMalignant NeoplasmsMapsModificationMolecular ChaperonesMulticentric Angiofollicular Lymphoid HyperplasiaMutationNamesNucleosomesOralOral cavityPalate Kaposi&aposs SarcomaPathogenesisPathologyPathway interactionsPatientsPatternPhenotypePlayPost-Translational Protein ProcessingPrimary InfectionProcessRecombinantsRecurrenceRegulationRoleSalivaSamplingSiteSmall Interfering RNASpecimenTestingTherapeuticTransformed Cell LineTranslatingVariantViralViral Gene Expression RegulationViral GenesViral GenomeViral ProteinsVirusWorkantiretroviral therapybasecell typecentromere protein Achromatin remodelingcollegecomparativeepigenomegene productin vivoknock-downlatency-associated nuclear antigenlatent infectionloss of functionlytic gene expressionlytic replicationmalignant mouth neoplasmneoplastic cellnew therapeutic targetnoveloral cavity epitheliumprimary effusion lymphomatransmission processtumorviral transmission
项目摘要
Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS),
and two lymphoproliferative diseases: primary effusion lymphoma (PEL) and multicentric Castleman's
disease (MCD). KS is the most common oral cancer in human immunodeficiency virus (HIV)-infected
patients. The oral cavity is the major site for virus transmission via saliva. Although the incidence of
AIDS-KS cases has been reduced in the US due to combination antiretroviral therapy (cART), recent
studies suggest recurrence of oral KS in long-term treated AIDS patients. While KS tumor cells are
mostly latently infected, and express a limited number of viral genes, gingival epithelial cells in the
oral cavity actively replicate KSHV which is important for a) seeding the latency reservoir in B cells
after primary infection and b) shedding in the oral cavity and transmission via saliva. Epigenetics and
chromatin structure play a central role in the regulation of both transcription and replication.
Deregulation, aberrant deposition, and mutations of histone variants such as H3.3, CENP-A, and
H2A.Z and their associated chaperones have been implicated in multiple human cancers
including head and neck. After de novo infection, KSHV genomes rapidly associate with
nucleosomes which acquire specific epigenetic modifications that partition the viral episome into
transcriptionally active and silenced domains. While multiple KSHV epigenetic marks have
been mapped in lymphoid, epithelial and endothelial cells, the processes and potential host-
viral interactions leading to the formation of latency permissive episomes are still poorly
understood. Given that the KSHV latency-associated nuclear antigen (LANA) interacts with
both chromatin remodelers and H3.3 histone chaperones Daxx, HIRA, and DEK, we
hypothesize that H3.3 deposition plays an important role in the establishment and maintenance
of KSHV latency. Our preliminary data demonstrate that H3.3 deposition on KSHV episomes can
be detected early after de novo infection on episomes of long-term infected cells. Moreover, we
demonstrated that genetically disrupting the H3.3 chaperone pathways HIRA and Daxx by
CRISPR/Cas9 leads to marked changes in KSHV latency control, associated with alterations in
the epigenetic status. We further hypothesize that latency-associated gene products including
LANA modulate and or de-regulate histone chaperone pathways during de novo infection and
latency. To directly address this hypothesis we propose to mechanistically study histone H3.3
deposition and the formation of histone post translational modifications (PTMs), with the goal of
understanding their relationship with respect to viral gene expression and latent/lytic
replication. A main aspect of these studies is to investigate how viral gene products interact with
and modulate histone variant chaperone pathways. In addition, we use human oral primary epithelial
cells which are more lytic than transformed epithelial cell lines to characterize epigenetic
changes responsible for their lytic phenotype. Importantly, through a collaboration with Dr.
Donald Cohen, College of Dentistry, we propose to establish in vivo epigenomes of oral KS in both
formalin-fixed and snap frozen tumor samples. The overall goal is to investigate how histone
variant deposition determines latent and lytic infection in a cell type-specific manner. The results
may point to KSHV-specific novel therapeutic targets for oral KS.
抽象的
Kaposi的肉瘤相关疱疹病毒(KSHV)是Kaposi的肉瘤(KS)的病因学者,
和两种淋巴增生性疾病:一级积液淋巴瘤(PEL)和多中心castleman的疾病
疾病(MCD)。 KS是人类免疫缺陷病毒(HIV)感染的最常见的口腔癌
患者。口腔是通过唾液传播病毒的主要部位。虽然发生率
由于联合抗逆转录病毒疗法(CART),美国的AIDS-KS病例已减少
研究表明,长期治疗的艾滋病患者的口服KS复发。而KS肿瘤细胞是
主要感染了潜在的感染,并表达有限数量的病毒基因,牙龈上皮细胞
口腔积极复制KSHV,这对于A)在B细胞中播种潜伏期储存库很重要
原发性感染和b)在口腔中脱落并通过唾液传播。表观遗传学和
染色质结构在转录和复制的调节中起着核心作用。
H3.3,CENP-A和
H2A.Z及其相关的伴侣与多种人类癌症有关
包括头和颈。从头感染后,KSHV基因组迅速与
核小体获得特定的表观遗传修饰,将病毒偶发分配到
转录活性和沉默的域。而多个KSHV表观遗传标记具有
被映射在淋巴样,上皮和内皮细胞中,过程和潜在宿主 -
病毒相互作用导致形成潜伏期允许的发作仍然很差
理解。鉴于KSHV潜伏相关的核抗原(LANA)与
染色质重塑剂和H3.3组蛋白伴侣DAXX,HIRA和DEK,我们
假设H3.3沉积在建立和维护中起着重要作用
KSHV延迟。我们的初步数据表明,H3.3对KSHV促进的沉积可以
从从头感染后早期就长期感染细胞的发作。而且,我们
证明,通过基因破坏H3.3伴侣途径Hira和Daxx
CRISPR/CAS9导致KSHV延迟控制的明显变化,与改变有关
表观遗传状态。我们进一步假设与潜伏期相关的基因产物,包括
LANA在从头感染期间调节和 /或脱离调节组蛋白伴侣途径
潜伏期。为了直接解决这一假设,我们提出机械学研究组蛋白H3.3
沉积和组蛋白的形成后翻译后修饰(PTMS),目的是
了解他们在病毒基因表达和潜在/裂解方面的关系
复制。这些研究的一个主要方面是研究病毒基因产物如何与
并调节组蛋白变体伴侣途径。此外,我们使用人类口服主要上皮
比转化的上皮细胞系更裂解的细胞表征表观遗传
负责其裂解表型的变化。重要的是,通过与Dr.
牙科学院唐纳德·科恩(Donald Cohen
福尔马林固定和快照冷冻的肿瘤样品。总体目标是研究组蛋白
变体沉积以细胞类型特异性方式决定潜在和裂解感染。结果
可能指出针对口服KS的KSHV特异性新型治疗靶标。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Coordination of transcription, processing, and export of highly expressed RNAs by distinct biomolecular condensates.
- DOI:10.1042/etls20190160
- 发表时间:2020-12-11
- 期刊:
- 影响因子:3.8
- 作者:Ishov AM;Gurumurthy A;Bungert J
- 通讯作者:Bungert J
Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer.
- DOI:10.1038/s41419-022-05312-8
- 发表时间:2022-10-13
- 期刊:
- 影响因子:9
- 作者:Sarwar, Sadia;Morozov, Viacheslav M.;Purayil, Hamsa;Daaka, Yehia;Ishov, Alexander M.
- 通讯作者:Ishov, Alexander M.
Sex-biased expression is associated with chromatin state in D. melanogaster and D. simulans.
性别偏向表达与黑腹果蝇和拟果蝇中的染色质状态相关。
- DOI:10.1101/2023.01.13.523946
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Nanni,AdalenaV;Martinez,Natalie;Graze,Rita;Morse,Alison;Newman,JeremyRB;Jain,Vaibhav;Vlaho,Srna;Signor,Sarah;Nuzhdin,SergeyV;Renne,Rolf;McIntyre,LaurenM
- 通讯作者:McIntyre,LaurenM
Super-enhancer mediated regulation of adult β-globin gene expression: the role of eRNA and Integrator.
- DOI:10.1093/nar/gkab002
- 发表时间:2021-02-22
- 期刊:
- 影响因子:14.9
- 作者:Gurumurthy A;Yu DT;Stees JR;Chamales P;Gavrilova E;Wassel P;Li L;Stribling D;Chen J;Brackett M;Ishov AM;Xie M;Bungert J
- 通讯作者:Bungert J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROLF F RENNE其他文献
ROLF F RENNE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROLF F RENNE', 18)}}的其他基金
Noncoding RNAs in gamma-Herpesvirus Biology and AIDS Malignancies
γ-疱疹病毒生物学和艾滋病恶性肿瘤中的非编码 RNA
- 批准号:
10812041 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
"Project 1" KSHV short and long noncoding RNAs and alteration of host IncRNA expression
“项目 1”KSHV 短非编码 RNA 和长非编码 RNA 以及宿主 IncRNA 表达的改变
- 批准号:
10865781 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
"Project 1" KSHV short and long noncoding RNAs and alteration of host IncRNA expression
“项目 1”KSHV 短非编码 RNA 和长非编码 RNA 以及宿主 IncRNA 表达的改变
- 批准号:
10403015 - 财政年份:2017
- 资助金额:
$ 35.53万 - 项目类别:
"Project 1" KSHV short and long noncoding RNAs and alteration of host IncRNA expression
“项目 1”KSHV 短非编码 RNA 和长非编码 RNA 以及宿主 IncRNA 表达的改变
- 批准号:
10646225 - 财政年份:2017
- 资助金额:
$ 35.53万 - 项目类别:
Noncoding RNAs in gamma-Herpesvirus Biology and AIDS Malignancies
γ-疱疹病毒生物学和艾滋病恶性肿瘤中的非编码 RNA
- 批准号:
10646224 - 财政年份:2017
- 资助金额:
$ 35.53万 - 项目类别:
Noncoding RNAs in gamma-Herpesvirus Biology and AIDS Malignancies
γ-疱疹病毒生物学和艾滋病恶性肿瘤中的非编码 RNA
- 批准号:
10818838 - 财政年份:2017
- 资助金额:
$ 35.53万 - 项目类别:
相似国自然基金
基于PET/MR影像基因组学的TP53/ATRX基因表达对低级别胶质瘤恶性转化的识别研究
- 批准号:82001769
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
IDH1基因突变在ATRX缺失胶质瘤生长和进展中的作用与机制
- 批准号:81672783
- 批准年份:2016
- 资助金额:51.0 万元
- 项目类别:面上项目
ATRX/DAXX/H3.3基因突变在端粒延长替代机制和肿瘤发生中的作用研究
- 批准号:81502420
- 批准年份:2015
- 资助金额:16.5 万元
- 项目类别:青年科学基金项目
Atrx 基因失活促进脑胶质瘤形成的表观遗传学机制研究
- 批准号:81472344
- 批准年份:2014
- 资助金额:68.0 万元
- 项目类别:面上项目
ATRX基因突变与端粒ALT相关性对胶质瘤发生和发展的影响
- 批准号:81341059
- 批准年份:2013
- 资助金额:10.0 万元
- 项目类别:专项基金项目
相似海外基金
Dissecting the Determinants of IDH-mutant Gliomas Response to Mutant IDH Inhibitors
剖析 IDH 突变型胶质瘤对突变 IDH 抑制剂反应的决定因素
- 批准号:
10734393 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
Understanding the impact of DNA ADP-ribosylation on telomere function in cancer cells
了解 DNA ADP-核糖基化对癌细胞端粒功能的影响
- 批准号:
10751121 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
Exploring p53-mediated ferroptosis to treat IDH1-mutant glioma
探索 p53 介导的铁死亡治疗 IDH1 突变神经胶质瘤
- 批准号:
10588005 - 财政年份:2023
- 资助金额:
$ 35.53万 - 项目类别:
Role of ATRX, a chromatin remodeler, in immunotherapy response
ATRX(染色质重塑剂)在免疫治疗反应中的作用
- 批准号:
10367734 - 财政年份:2022
- 资助金额:
$ 35.53万 - 项目类别: